Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report.
- Resource Type
- Article
- Authors
- Makiguchi, Tomonori; Fukushima, Takashi; Tanaka, Hisashi; Taima, Kageaki; Takayasu, Shinobu; Tasaka, Sadatomo
- Source
- Thoracic Cancer. Apr2022, Vol. 13 Issue 8, p1220-1223. 4p.
- Subject
- *LUNG cancer diagnosis
*THERAPEUTIC use of monoclonal antibodies
*CELL differentiation
*COVID-19 vaccines
*MONOCLONAL antibodies
*RISK assessment
*MESSENGER RNA
*MEMBRANE proteins
*DIABETIC acidosis
*NANOPARTICLES
*IMMUNOTHERAPY
- Language
- ISSN
- 1759-7706
We describe a case of diabetic ketoacidosis (DKA) shortly after the SARS‐CoV‐2 (COVID‐19) vaccination in a 65‐year‐old woman with non–small‐cell lung cancer under a combination treatment of programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) inhibitors. She had no history of diabetic mellitus. A few days after the second shot of COVID‐19 vaccination, she developed DKA. We speculate that the immune‐related adverse event and immunogenicity of vaccination synergistically induced DKA. [ABSTRACT FROM AUTHOR]